| Drug Name |
Bexarotene |
| Drug ID |
BADD_D00269 |
| Description |
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. |
| Indications and Usage |
Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XF03 |
| DrugBank ID |
DB00307
|
| KEGG ID |
D03106
|
| MeSH ID |
D000077610
|
| PubChem ID |
82146
|
| TTD Drug ID |
D0N0RU
|
| NDC Product Code |
14593-920; 69988-0006; 69238-2088; 68554-0081; 0378-6955; 68682-002; 0591-2832; 10888-8226; 14096-150; 42291-072; 0054-0399; 0832-0285; 11014-0014; 61474-4298; 0187-5525; 0187-5526; 10888-5128; 67262-0005; 68682-003; 69238-1250; 10888-8105; 11014-0435; 54893-0035; 43975-315 |
| UNII |
A61RXM4375
|
| Synonyms |
Bexarotene | 3-methyl-TTNEB | 4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid | LG69 compound | LGD 1069 | LGD-1069 | LGD1069 | Targretin |
